Fundraising Fox

Arvinas Holding Co. LLC

NASDAQ: ARVN

New Haven, US · Founded 2014 · Delaware corporation · 6 known investors

arvinas.com ↗

Arvinas is a clinical-stage biopharmaceutical company developing PROTAC protein degrader therapies for oncology and neurology. The company focuses on discovering and developing novel investigational drugs for patients with limited or ineffective treatment options.

Biotechin /arvinas@ArvinasInc

Founders & leadership

SS
Stephen SquintoDirector
LR
Liam RatcliffeDirector
AL
Andrew LevinDirector
SC
Sean CassidyExecutive Officer
JS
Jonathan SoderstromDirector
BM
Brad MargusDirector
ML
Manuel LitchmanExecutive Officer, Director
KP
Kush ParmarDirector
TS
Tim ShannonDirector

Investors · 6

Access BiotechnologyNew York City
Canaan PartnersStamford · $500K – $20Mvia Tim Shannon · board
Connecticut InnovationsNew Haven · $500K – $2M
Nextech InvestZurich · $648K – $3.2M
Solasta VenturesBoston
OrbiMedreportedNew York · $1M – $75Mvia Stephen Squinto · board

Reported raises · per SEC filings

Form D private placements
▶$32.5MraisedJul 2019 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John G. HoustonExecutive Officer, Director
  • Sean CassidyExecutive Officer
  • Bradley MargusDirector
  • Kush ParmarDirector
  • Timothy ShannonDirector
  • Edward Kennedy, Jr.Director
  • Briggs MorrisonDirector
  • Liam RatcliffeDirector
  • Jakob LovenDirector
  • Ian TaylorExecutive Officer
Offering amount
$32.5M
Amount sold
$32.5M
First sale
Jul 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$55MraisedApr 2018 · 22 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew LevinDirector
  • Sean CassidyExecutive Officer
  • Tim ShannonDirector
  • Kush ParmarDirector
  • Jakob LovenDirector
  • Liam RatcliffeDirector
  • Stephen SquintoDirector
  • John D. HoustonExecutive Officer, Director
  • Jonathan SoderstromDirector
  • Brad MargusDirector
Offering amount
$55M
Amount sold
$55M
First sale
Mar 2018
Incorporated
Limited Liability Company, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$41.6MraisedOct 2015 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen SquintoDirector
  • Liam RatcliffeDirector
  • Andrew LevinDirector
  • Sean CassidyExecutive Officer
  • Tim ShannonDirector
  • Jonathan SoderstromDirector
  • Brad MargusDirector
  • Manuel LitchmanExecutive Officer, Director
  • Kush ParmarDirector
Offering amount
$41.6M
Amount sold
$41.6M
First sale
Oct 2015
Incorporated
Limited Liability Company, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news